Acepodia's Approach To ACC & CAR Manufacturing Scalability
Source: Bioprocess Online
Acepodia CEO, President, & Co-founder Dr. Sony Hsiao and Dr. Mark Gilbert, SVP of R&D, join Erin Harris and Matt Pillar for a discussion on the company's approach to dramatically reducing the cost of cell therapy development, manufacturing, and administration via its oNK, CAR, and ACC candidates.
This website uses cookies to ensure you get the best experience on our website. Learn more